Skip to main content
. 2010 Sep;161(1):207–228. doi: 10.1111/j.1476-5381.2010.00889.x

Table 5.

Inhibition of hU-II-induced contraction of isolated arteries from cat, monkey and human UT transgenic mouse by GSK1440115

hU-II Emax (% KCl) hU-II pEC50
[GSK1440115] nM Vehicle-treated control GSK1440115-treated Vehicle-treated control GSK1440115-treated pA2
Cat
Femoral artery (n= 5) 1 000 134 ± 11 161 ± 26 9.69 ± 0.15 8.28 ± 0.15 7.39 ± 0.16
Thoracic aorta (n= 5) 10 000 161 ± 13 173 ± 34 9.03 ± 0.08 8.33 ± 0.07 5.59 ± 0.12
Mesenteric resistance artery (n= 3) 1 000 59 ± 10 60 ± 4 9.56 ± 0.18 7.84 ± 0.13 7.71 ± 0.06
Monkey
Renal artery (n= 4) 10 000 133 ± 34 109 ± 14 9.46 ± 0.08 7.82 ± 0.12 6.63 ± 0.16
Superior mesenteric artery (n= 4) 10 000 178 ± 19 158 ± 37 9.27 ± 0.16 7.80 ± 0.23 6.46 ± 0.09
Human UT transgenic mouse
Thoracic aorta (n= 5) 10 000 128 ± 7 158 ± 16 9.15 ± 0.06 6.73 ± 0.07 7.41 ± 0.06

All values are expressed as mean ± SEM. Statistical comparisons of Emax values were performed using paired, two-tailed t-tests and no values were determined different from vehicle control values (P > 0.05). Competitive antagonist affinities (pA2) were determined using the Schild equation (Jenkinson et al., 1998).